Anwendung von immunmodulatorischen Systemtherapien in der täglichen dermatologischen Praxis

• Antibiotika
• Clindamycin
• Rifampicin
• Tetrazykline (Doxycyclin) (Doxakne®, Oraycea®)
• Kleine Moleküle
• Acitretin (Acicutan®, Neotigason®)
• Alitretinoin (Toctino®, Alitrederm®)
• Apremilast (Otezla®)
• Azathioprin (Azafalk®, Azaimmun®)
• Ciclosporin A (Sandimmun®, Ciquorin®, weitere)
• Colchizin
• Dapson
• Dimethylfumarat, Fumarsäureester und -salze (Skilarence®, Fumaderm®)
• Hydroxychloroquinsulfat (Plaquenil®, Quensyl®, Aristo®)
• Isotretinoin (IsoGalen®, Isoderm®, Aknenormin®)
• Kalium Iodatum
• Methotrexat (Lantarel®, Metotrexamend®, Metex®, Trexject®, weitere)
• Mycophenolat mofetil (Cellcept®, Mycophenplat®, Mowel®, Myfenac®, weitere)
• Biologika
• Anti-TNF-α
• Adalimumab ADA (z.B. Humira®)
• Certolizumab pegol CZP (Cimzia®)
• Etanercept ETA (z.B. Enbrel®)
• Infliximab IFX (z.B. Remicade®)
• Anti-IL-23-Antikörper
• Guselkumab (Tremfya®)
• Risankizumab (Skyrizi®)
• Tildrakizumab (Ilumetri®)
• Ustekinumab (Stelara®)
• Anti-IL17A- und Anti-IL17- Rezeptor-Antikörper
• Bimekizumab BKZ (Bimzelx®)
• Brodalumab (Kyntheum®)
• Ixekizumab (Taltz®)
• Secukinumab (Cosentyx®)
• Anti-IL1-Antikörper/Inhibitoren
• Anakinra (Kineret®)
• Canakinumab (Ilaris®)
• Anti-IL36-Antikörper
• Spesolimab (Spevigo® von Boehringer Ingelheim)
• Anti-IL-4/-13-Antikörper
• Dupilumab (Dupixent®)
• Lebrikizumab (Ebglyss® von Almirall)
• Tralokinumab (Adtralza®)
• Anti-CD20-IgG
• Rituximab (z.B. MabThera)
• Humane Immunglobuline
• Intravenöse Immunglobuline (IVIG) (Intratect®, Privigen®, Octagam®, Gamunex®)
• Anti-IgE
• Omalizumab (Xolair®)
• Januskinase-Inhibitoren
• Abrocitinib (Cibiniqo®)
• Avapritinib (Ayvakyt®)
• Baricitinib (Olumiant®)
• Deucravacitinib (Sotyktu®)
• Ritlecitinib (Litfulo®)
• Tofacitinib (Xeljanz®)
• Upadacitinib (Rinvoq®)